TCR T cell therapy is a powerful tool that can redirect patients’ immune cells to target cancer cells. Conventional assays such as affinity measured by SPR do not always correlate with in vivo results, so the selected candidates might turn out not to be the best one. Our cell avidity expert, Dr. Will Singleterry, will present the insights cell avidity experiments provided for the team of Dr. Nathalie Rufer at University of Lausanne in this webinar.
Key learning points:
- In contrast to affinity measured by SPR, cell avidity measurements directly correlate with T-cell functionality.
- Avidity is a reliable parameter for the selection of top TCR candidates.
- Cell avidity measurements with the z-Movi Cell Avidity Analyzer can accelerate the characterization of TCR-engineered T cells with anti-tumor activity and immunotherapeutic potential, through a fast and high-throughput workflow.
